Phagenesis closes €7m series B funding round
This article was originally published in Clinica
Dysphagia specialist Phagenesis has closed a €7m ($9.3m) series B funding round. The Manchester, UK company aims to accelerate the development of an innovative device that aids swallowing through electrical stimulation. The device, which “delivers a precisely sequenced and calibrated electrical signal to the pharynx of the dysphagic patient”, has demonstrated safety and efficacy in helping the patient to swallow. The investment is led by life science fund Inventages, with the participation of existing shareholders. Phagenesis is “ideally-placed” to address a “critical unmet need in a very large market”, said Inventages founder Gunnar Weikert. Ashok Dhanrajgir, senior partner at Inventages, will join Phagenesis as board director.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.